I am currently taking quetiapine (Seroquel) 100 mg nightly and still experiencing sundowning; how should I manage it?

Management of Persistent Sundowning on Quetiapine 100mg

Before increasing or continuing quetiapine, you should first prioritize non-pharmacological interventions and environmental modifications, as the evidence for quetiapine's efficacy in sundowning is weak while its risks in elderly patients with dementia are substantial.

Critical Safety Concerns with Current Quetiapine Use

The FDA label explicitly warns that antipsychotics like quetiapine increase stroke risk and mortality in elderly patients with dementia 1. Recent high-quality evidence from 2025 demonstrates that even low-dose quetiapine (your current 100mg dose) significantly increases:

• All-cause mortality (HR 3.1 compared to trazodone) 2
• New-onset dementia (HR 8.1 vs trazodone, HR 7.1 vs mirtazapine) 2
• Falls (HR 2.8 vs trazodone) 2
• Weight gain and metabolic dysfunction even at doses <200mg 3

Why Quetiapine May Not Be Working

Sundowning remains poorly understood with unclear etiology 4, 5. Quetiapine is commonly prescribed off-label for sleep/agitation in dementia 6, but this practice is "understudied and not without risk" 6. A 2024 systematic review found that exploratory studies suggesting quetiapine's promise for off-label indications (including behavioral symptoms) were rarely followed by confirmatory trials—79% of indications lacked large confirmatory evidence within 5 years 7.

Recommended Management Algorithm

Step 1: Implement Environmental Interventions First

The 2002 Alzheimer's guidelines emphasize that both mild and severe agitation should be managed with environmental interventions 8:

• Structured activities during late afternoon/evening hours
• Increased light exposure during daytime
• Supervision and environmental safety modifications
• Education and support for caregivers
• Avoid overstimulation in evening hours

Step 2: If Medication Needed, Consider Safer Alternatives

For mild-to-moderate agitation/sundowning:

• Trazodone is associated with significantly lower mortality and fall risk compared to quetiapine 2
• Mirtazapine (7.5-30mg at bedtime) is better tolerated and promotes sleep 8 with lower dementia risk than quetiapine 2

If switching from quetiapine:

• Taper quetiapine over 10-14 days to avoid withdrawal symptoms (insomnia, nausea, vomiting) 1
• Start alternative agent at low dose

Step 3: If Antipsychotic Absolutely Required

Only consider continuing/adjusting antipsychotics if:

• Severe agitation with risk of harm to self/others
• Psychotic features are present
• Non-pharmacological and other medication trials have failed

If continuing quetiapine despite risks:

• The guidelines suggest medication adjustments every 5-7 days until therapeutic benefit or side effects appear 8
• However, given the 2025 safety data, switching to trazodone or mirtazapine is strongly preferred over dose escalation

Common Pitfalls to Avoid

1. Don't assume the current dose is inadequate without trying environmental interventions first—sundowning may respond better to non-pharmacological approaches
2. Don't increase quetiapine dose—higher doses increase metabolic and neurological risks without proven benefit for sundowning
3. Don't continue indefinitely—guidelines recommend reassessing need after 9 months with dose reduction 8
4. Don't ignore the black box warning—elderly patients with dementia-related psychosis have increased mortality risk with antipsychotics 1

Bottom Line

Switch from quetiapine to trazodone or mirtazapine while maximizing environmental interventions, given the substantial mortality, dementia, and fall risks associated with quetiapine in elderly patients that outweigh its unproven benefits for sundowning 2.